Comparing the current results to its competitors, Adaptive Biotechnologies reported Revenue increase in the 2 quarter 2026 by 21.53 % year on year. The sales growth was above Adaptive Biotechnologies's competitors' average revenue growth of 19.11 %, achieved in the same quarter.
Adaptive Biotechnologies's Comment on Competition and Industry Peers
The company operates in a competitive environment within immune medicine, facing competition from life sciences tools, diagnostics, pharmaceutical and biotechnology companies, academic research institutions, and governmental and private research institutions. Its clonoSEQ test competes in clinical diagnostics primarily against conventional and next-generation flow cytometry methods used in-house or through reference laboratories and contract research organizations. Additional competition arises from new market entrants developing blood-based disease monitoring tools based on protein markers, circulating tumor DNA, or circulating tumor cells. Potential future competitors include companies offering early cancer detection tests for indications not currently addressed by clonoSEQ, such as minimal residual disease (MRD) assessment for solid tumors. The immune medicine sector includes several biotechnology firms and large-cap biopharmaceutical companies, many with substantially greater resources.
In an era where personalized medicine is gaining traction, Adaptive Biotechnologies, a leader in immune-driven medicine, has been making significant strides. In collaboration with other industry partners, the company has presented more than 30 abstracts at the 65th ASH Annual Meeting, showcasing the actionability of clonoSEQ MRD testing in blood cancer patient care and drug development. This breakthrough technology has the potential to revolutionize the way blood cancers are diagnosed, monitored, and treated. Additionally, Adaptive Biotechnologies latest financial results indicate a competitive edge despite a decrease in revenue, signifying the company s continued dedication to innovation and grow...
Sensei Biotherapeutics Inc is a biotechnology company that focuses on developing personalized and targeted cancer therapies. They employ a unique approach called ImmunoPhage, which utilizes bacteriophages to specifically target tumor antigens and stimulate an immune response. Their business model revolves around conducting research and clinical trials to bring innovative cancer treatment options to market.
Pacific Biosciences Of California Inc Share Performance
+1.19%
One Year
Pacific Biosciences Of California Inc
Profile
Pacific Biosciences of California Inc's business model revolves around the development and commercialization of innovative sequencing systems that enable scientists and researchers to study the complexity of biology. They provide high-resolution genetic analysis solutions, offering a comprehensive platform that includes consumables, systems, and data analysis software to support genomic analysis.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Sources:
Adaptive Biotechnologies Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Adaptive Biotechnologies Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
